IELSG32 - Randomised phase II trial on initial therapy with high-dose methotrexdate and high-dose cytarabine with or without thiotepa and/or rituximab, followed by brain irradiation vs. autologous stem cells transplantation for primary CNS lymphoma
Persone
Zucca E.
(Responsabile)
Informazioni aggiuntive
Acronimo
IELSG32
Data d'inizio
01.01.2011
Data di fine
01.01.2014
Durata
36 Mesi
Enti finanziatori
SNSF
Stato
Concluso
Categoria
Swiss National Science Foundation /
Project Funding /
Life Sciences (Division III)
